**Name of Journal: *World Journal of Gastroenterology***

**ESPS Manuscript NO: 20906**

**Manuscript Type: Review**

**Gender difference in gastro-esophageal reflux diseases**

Asanuma K *et al*. Estrogen’s role in male predominance

Kiyotaka Asanuma, Katsunori Iijima, Tooru Shimosegawa

**Kiyotaka Asanuma, Katsunori Iijima, Tooru Shimosegawa,** Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-mach Aobaku Sendai, Miyagi [Prefecture](http://www.baidu.com/link?url=CCm8NUDtkc3aaZzRtvJAdtc6LR0G-mlGsiSUtp7qok4qqrv644PGhGs8V6JIKvuIZcyx5hQsKmQFK2P-OR9yy4sWrDMDOxuxICuen_5L2TK) 980-8574, Japan

**Author contributions:** Asanuma K drafted and edited this review; Iijima K edited and critically revised this manuscript; and Shimosegawa T approved the final version.

**Conflict-of-interest statement:** Authors declare no conflict of interest for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Iijima Katsunori, MD,** Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aobaku, Sendai, Miyagi Prefecture 980-8574, Japan. kiijima@med.tohoku.ac.jp

**Telephone:** +81-22-7177171

**Fax:** +81-22-7177177

**Received:** June 25, 2015

**Peer-review started:** June 27, 2015

**First decision:** September 9, 2015

**Revised:** October 7, 2015

**Accepted:** December 30, 2015

**Article in press:**

**Published online:**

**Abstract**

The incidence of esophageal adenocarcinoma (EAC) has risen sharply in western countries over the past 4 decades. This type of cancer is considered to follow a transitional process that goes from gastro-esophageal reflux disease (GERD) to Barrett’s esophagus (BE, a metaplastic condition of the distal esophagus), a precursor lesion and ultimately adenocarcinoma. This spectrum of GERD is strongly predominant in males due to an unidentified mechanism. Several epidemiologic studies have described that the prevalence of GERD, BE and EAC in women is closely related to reproductive status, which suggests a possible association with the estrogen level. Recently, we revealed in an *in vivo* study that the inactivation of mast cells by the anti-inflammatory function of estrogen may account for the gender difference in the GERD spectrum. Other studies have described the contribution of female steroid hormones to the gender difference in these diseases. Estrogen is reported to modulate the metabolism of fat, and obesity is a main risk factor of GERDs. Moreover, estrogen could confer esophageal epithelial resistance to causative refluxate. These functions of estrogen might explain the approximately 20-year delay in the incidence of BE and the subsequent development of EAC in women compared to men, and this effect may be responsible for the male predominance. However, some observational studies demonstrated that hormone replacement therapy exerts controversial effects in GERD patients. Nevertheless, the estrogen-related endocrine milieu may prevent disease progression toward carcinogenesis in GERD patients. The development of innovative alternatives to conventional acid suppressors may become possible by clarifying the mechanisms of estrogen.

**Key word:** gastro-esophageal reflux disease; Barrett's esophagus; esophageal adenocarcinoma; estrogen; male predominance

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Gastro-esophageal reflux disease (GERD), Barrett's esophagus and esophageal adenocarcinomaare epidemiologically recognized to be more prevalent in males due to an unknown mechanism. Our recent animal study revealed that estrogen contributes to the gender difference by inactivating inflammatory cells. Additionally, several studies demonstrated that estrogen confers epithelial resistance against causative refluxate and modifies adipose tissue metabolism in obese people and prevent the onset of GERDs. Consequently, the estrogen-related endocrine milieu in women could retard the progression of chronic inflammation to esophageal carcinogenesis, which is likely responsible for the predominance of GERD in males.

Asanuma K, Iijima K, Shimosegawa T. Gender difference in gastro-esophageal reflux diseases. *World J Gastroenterol* 2015; In press

**Introduction**

Esophageal adenocarcinoma (EAC) has been increasing in many countries, especially in western countries, over the past 4 decades[1,2]. EAC has been proposed to be the end result of a stepwise disease process that transitions through gastro-esophageal reflux disease (GERD) and Barrett’s esophagus (BE), a condition in which the reflux-damaged esophageal squamous epithelium is replaced by metaplastic columnar epithelium[3]. EAC, erosive reflux esophagitis (ERD) and BE are widely known to be predominant in males. This gender difference in the spectrum of GERD cannot be explained by prevailing risk factors and has previously been associated with sex steroid hormones, although little is known about the mechanism responsible for this disparity in the incidence. Some types of human gastro-intestinal neoplasms are predominant in males, including colorectal cancer, gastric cancer and esophageal cancer[4-6]. The gender-specific susceptibility to various diseases in the gastro-intestinal tract has frequently been investigated using experimental animal models[7,8]. Females are less affected by gastric or intestinal inflammation in response to chemical insult or bacterial infection than males are, which leads to differences in the incidence of gender-specific carcinogenesis[9]. In these studies, the anti-inflammatory activity of estrogen was considered to contribute to the lower incidence of carcinogenesis in females.

Using an animal model of GERD, we recently published the first report showing that the estrogen level could account for the gender difference in disease incidence[10]. In this review, we describe the crucial role of estrogen, a primary female sex hormone that exerts various physiological activities, including anti-inflammatory functions, in the sex difference of GERD incidence.

**Epidemiology in GERD, Barrett’s Esophagus and Esophageal Adenocarcinoma**

Accumulating epidemiological evidence shows that the generative period of women is related to the prevalence of GERDs. The difference in age-stratified prevalence between the sexes suggests that estrogen significantly impacts each step of GERD-related carcinogenesis and may consequently be responsible for the predominance of this disease in males.

***GERD***

GERD consist of manifestations of esophageal damage due to the reflux of gastric or intestinal contents to the esophagus as well as other symptoms, especially heartburn[11]. The incidence of GERD has been reported to be almost equal in males and females[12]. However, GERD is grossly divided into 2 pathological conditions by endoscopy, erosive reflux esophagitis (ERD) and non-erosive reflux esophagitis (NERD), and epidemiologic studies have indicated that ERD is predominant in males (Table 1)[13-21]. A recent meta-analysis described that the male/female ratio in the prevalence of ERD was 1.57/1 (95%CI: 1.40-1.76)[22], and the mean age of men with ERD was reported to be lower than that of women. A retrospective, large-scale endoscopic analysis in the UK showed that the mean age of men/women with ERD was 59.7 ± 16.1/64.4 ± 15.1[18]. Thus, the incidence of ERD positively correlated with age, but female patients tended to be older than male patients[18,19,23]. Moreover, ERD tended to be more severe in older women than in men, and the increase in the incidence of severe ERD tended to be higher in postmenopausal women than in men[18,19]. Conversely, NERD is more common in women (Table 1)[12,16,24,25]. Interestingly, a quantitative esophageal symptom analysis revealed that symptom frequency and severity were significantly higher in women than in men, whereas the endoscopic esophagitis grade or duration of the time at pH below 4 during ambulatory 24-h esophageal pH monitoring did not significantly differ between men and women[14,26].

***BE***

The prevalence of BE is not known, in part because this disease is symptomatically silent, which complicates endoscopic studies. Furthermore, the definitions of BE often differ by study. United States gastroenterology societies require esophageal biopsies showing intestinal metaplasia (IM) and goblet cells for a definitive diagnosis of BE because IM is considered a well-established risk factor for adenocarcinoma[27,28]. Conversely, the British Society of Gastroenterology guidelines noted that the presence of IM in the columnar epithelium of the esophagus is not a prerequisite for the diagnosis of BE due to the difficulty in excluding sampling errors of the biopsies and the carcinogenic potential in non-IM[29]. In women, the prevalence of BE, defined as columnar lined epithelium (CLE) with IM, has been reported to be approximately twice as high as in men (Table 2)[30-43]. Specifically, a meta-analysis demonstrated that the male/female sex ratio of BE with IM was 2.13/1 (95%CI: 1.87-2.46)[22]. A large cohort study in the Netherlands revealed that the mean age of women with BE was significantly higher than that of men with BE (men/women; 59.3 ± 13.8/65.5 ± 15.0, *p* < 0.01)[39]. Other studies revealed that the prevalence of BE in women began to increase after 60 years of age and that the increase in the prevalence of BE in women in the postmenopausal period surpassed that of men[17,34]. Age-specific increases in BE occurred in parallel with a 20-year age shift between men and women[34]. Moreover, BE tended to be longer in men than in women, and the incidence of BE with IM was higher in men than in women[34,44]. Conversely, epidemiologic studies of the prevalence of BE, irrespective of the presence of IM, demonstrated a significant male predominance, but the male/female ratio of this condition was somewhat lower than that of BE (Table 2)[45-47]. The meta-analysis revealed that the male/female ratio of BE was 1.71/1 (95%CI: 1.42-2.04), irrespective of the presence of IM[22].

***EAC***

The male/female ratio in the prevalence of EAC varies depending on the country or ethnicity (Table 3)[37,39,42,43,48-52]. Nevertheless, as a whole, EAC is significantly more common in males than in females, irrespective of country or ethnicity. In the United States, United Kingdom, Denmark and Sweden, the incidence of EAC has been increasing in both men and women, whereas the incidence in women has been almost stable or increasing at only a very low rate in Norway and Finland[1,2,49,53]. In Caucasians in the United States, England and Wales, where the rate of increase of EAC is higher than in other countries, the male/female ratio of 5/1 has not changed over the last 3 decades[48,49]. However, non-Caucasian men in the US have experienced a slow increase in the incidence of EAC, whereas the incidence in non-Caucasian women has remained almost unchanged over the last 3 decades. Therefore, the male/female ratio of EAC in non-Caucasians in the US ranged from 1.5/1 to 2.0/1 during the study period[48,49]. The mean age of female BE patients with EAC and high-grade dysplasia was reported to be higher than that of male BE patients (men/women: 64.1 ± 10.7/70.6 ± 7.9), and this trend was the same for other GERDs[44]. A recent large population-based study demonstrating the annual percentage change in the incidence of EAC revealed that the rate of EAC rapidly increased in men, regardless of age, whereas women aged 50 and older exhibited slowly increasing rates of EAC. However, the rate of increase was higher in women aged 80 years or older than in men, whereas women aged under 50 showed a qualitatively flatter trajectory[54]. Additionally, this study revealed that the age-adjusted male/female ratio of the incidence steadily declined starting at age 50, suggesting a disproportionate increase in the incidence of EAC in postmenopausal women. The combined evidence suggests that women lag behind men by 17 years in the development of EAC[55].

***Gender differences in the spectrum of GERD***

These epidemiologic studies have demonstrated a profound male predominance in the prevalence of GERD, including ERD, BE and EAC, irrespective of country, ethnicity and decade. The male to female ratio appears to increase as the disease progresses from ERD to BE and subsequent EAC; in other words, the reported male to female ratio in the prevalence of BE was higher than that of GERD, and the reported male to female ratio in the prevalence of EAC was higher than that of BE[22,37].

Moreover, these 3 reflux-associated disorders share one common feature: the severity and the prevalence of these diseases appear to be closely related to the reproductive hormone status of women. In the postmenopausal period, the prevalence of the GERD spectrum rapidly increased, whereas it was lower than that in men in the reproductive period, which could be responsible for the increased prevalence of GERDs in younger men than women and for dozen-year delay in the development of BE and EAC in women. Additionally, long-segment BE was more common in men than short-segment BE [34,44]. Sex hormones in women might prevent the development of IM by reducing ERD, which may be responsible for the difference in the prevalence of BE by definition. Considering the anti-inflammatory function of estrogen and the fact that severe reflux and esophageal inflammation are likely to promote the development of BE and subsequent EAC[56,57], these epidemiologic findings suggest that exposure to estrogen during the reproductive years may protect women from the progression of esophageal metaplasia to carcinogenesis.

**Smoking and Alcohol**

Esophageal malignant neoplasms can be roughly classified into two histological types of cancer, esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC), and both types are more common in males than in females[58]. Tobacco smoking and excessive alcohol consumption are widely recognized as risk factors for ESCC[59]. Moreover, the male predominance of ESCC is attributed to the higher prevalence of environmental risk factors in men, such as current or past tobacco smoking and the excessive consumption of alcohol[60]. Similarly, a number of observational studies have identified current or past tobacco smoking as a risk factor for EAC. In patients with BE, current and past smoking history increases the risk for progression to high-grade dysplasia and adenocarcinoma by approximately two-fold[61]. However, a recent cohort study reported that the male predominance in EAC could not be attributed to differences in smoking histories[62]. This study demonstrated a similar male predominance of EAC before and after adjusting for smoking (men/women ratio, 95%CI: before 9.9%, 6.5-15.1; after 8.7%, 5.7-13.4). On the other hands, some epidemiological studies showed that the excessive consumption of some types of alcohol, such as liquor, promoted the progression of BE to EAC[63]. Nevertheless, alcohol consumption has not been associated with the male/female ratio in GERD, BE and EAC.

**Obesity in the GERD spectrum**

Obesity is an important risk factor for GERD, BE and EAC. Consequently, this condition has garnered increasing attention, particularly because the incidence of these diseases increased in parallel with obesity[64,65]. To date, no single mechanism that can account for this profound increase has been identified, and the mechanism by which obesity promotes the development of BE and EAC remains unclear. Abdominal obesity has been hypothesized to induce GERD *via* mechanical mechanisms by increasing the abdominal pressure, which subsequently relaxes the lower esophageal sphincter to expose the lower esophagus to gastric acid and increase the risk of GERD and, consequently, BE[66-68]. Additionally, the contents of the duodenal juice that could reflux into the esophageal lumen may differ in obese individuals. A vagal abnormality associated with obesity may cause a high output of bile and pancreatic enzymes, thus making the refluxate more toxic to the esophageal mucosa[69].

In general, obesity is often evaluated using a proxy, the body mass index (BMI), and an increased BMI is fairly consistently associated with a higher risk of EAC[37,70]. However, recent studies have suggested that intra-abdominal or central obesity rather than BMI are more consistently associated with GERD and BE[32,71-73]. Another meta-analysis showed a strong relationship between central obesity and EAC after adjusting for BMI[74]. However, the association between BMI and GERD or BE has been inconsistent between the sexes[37,64, 65]. A case-controlled study conducted in Japan also demonstrated a strong association between BMI and BE in men, whereas these two factors were not associated in women[75]. Although abdominal obesity has been documented to be a risk for these diseases, independent of BMI, the precise mechanism responsible for the gender difference has yet to be determined. A recent study using the National Health and Nutrition Examination Survey data described that men predominantly display central obesity, which consists of mainly visceral adipose tissue, and this presentation is less common in women[76]. Abdominal obesity might cause mechanical dysfunction at the gastro-esophageal junction and make the gastro-duodenal reflux contents more harmful, which may partly explain the observed sex disparities in the disease.

Visceral fat is associated with particular metabolic compounds and a different balance of adipose-related hormones, including insulin-like growth factor, tumor necrosis factor α (TNF-α), and interleukin 6 (IL-6), and adipokines, such as leptin, many of which have also been found to be linked to carcinogenesis in other types of cancer[77,78]. Leptin, an adipokine, is secreted by adipocytes and regulates food intake and energy consumption[79]. In humans, the serum leptin level closely correlates with body fat mass, and obese people are typically hyperleptinemic, a condition that results from leptin resistance[79]. In an *in vitro* study, leptin was shown to be mitogenic and angiogenic; it was also shown to induce proliferation in a variety of human cell types, including esophageal cancer cell lines[80]. A recent case-controlled study revealed that higher concentrations of serum leptin were associated with an increased risk of BE[81]. In this study, the serum leptin levels positively correlated with the risk of BE in men, but this correlation tended to be negative in women[81]. Although the general serum leptin level in women is 3- to 4-fold higher than that in men, the incidence of BE is inversely related to the leptin level in women.

**Contribution of estrogen to the gender difference in the incidence of GERD spectrum**

***Obesity***

Estrogen is reported to be involved in the regulation of metabolism in adipose tissue[82]. An animal study using mice demonstrated that obesity was induced by reducing the ability to synthesize estrogen and by knocking out the estrogen receptor-α (ER-α)[83,84]. Additionally, estrogen increases the leptin mRNA levels in adipose tissue, and this deficiency impairs central leptin sensitivity[85,86]. Moreover, estrogen was found to influence leptin receptor expression and hypothalamic sensitivity to leptin, thus driving subcutaneous body fat accrual over visceral fat in a rat animal model to result in the inverse relationship between visceral fat and the estrogen level. Eventually, visceral fat accumulation becomes evident when the circulation estrogen levels are sufficiently low in postmenopausal women[87,88]. Differences in the distribution of body fat between men and women, i.e., the accumulation of visceral fat in men and subcutaneous fat in women, might account for the increased prevalence of some types of GERD-related disorders in men.

The relationship between leptin level and the difference in the prevalence of BE between the sexes is controversial. Although leptin induced the proliferation of ER-α-overexpressing mammary gland cells *in vitro* *via* signal transducer and activator of transcription 3 (STAT-3), which regulates inflammatory and apoptotic processes, it did not promote the proliferation of ER-α-overexpressing cells. Instead, leptin slightly decreased the proliferation of these cells[89]. Human esophageal epithelium predominantly expresses ER-α; thus, the higher concentration of estrogen in women prior to menopause than men might prevent the leptin-induced development of BE and, subsequently, EAC in women although further studies is needed to clarify the precise mechanism[90].

***Immune response***

Sex steroid hormones are well known to modulate the immune system in many organs[91]. Estrogen, a sex steroid hormone, has been reported to exhibit anti-inflammatory activity, such as reducing the migration, adhesion and production or secretion of chemical mediators. In our study, which utilized a rat model of surgically induced reflux esophagitis, we demonstrated that estrogen attenuates reflux esophagitis *via* the inactivation of mast cells, which express estrogen receptors and are ubiquitous in the esophageal epithelium[10]. This study revealed that female rats were significantly less damaged by reflux esophagitis than male rats, and ovariectomy in female rats diminished the attenuation of esophageal damage. Furthermore, the administration of estrogen to both ovariectomized rats and male rats suppressed reflux esophagitis-induced mucosal injury. We also revealed that estrogen inhibited TNF-α expression by mast cells in the context of reflux esophagitis, which alleviated esophageal damage. The direct impact of estrogen on mast cells is evidenced by the inhibition of cytokine production and the fact that mast cells are primarily involved in the initiation of tissue damage induced by reflux esophagitis[92,93]. Esophageal mast cells are an integral component of the estrogen-mediated response, which could result in the predominance of GERDs in males. Although this report is the first *in vivo* study to demonstrate the involvement of a sex hormone in the gender difference *via* the inactivation of inflammatory cells in GERD, other candidate mechanisms implicate sex steroid hormones in the prevention of the stepwise progression from GERD to EAC. Some studies demonstrated that estrogen repressed the monocyte/macrophage system in some pathological conditions involved in the development of postmenopausal disorders[94-96]. Our study, as described above, also revealed the involvement of tissue macrophage inhibitory factor (MIF) expression in a GERD animal model[10]. MIF is expressed by various cell types, including esophageal squamous cells, and regulates inflammation and the innate immune response involved in macrophage infiltration and TNF- production[97]. We revealed that estrogen significantly suppressed the esophageal MIF level. Because estrogen has been shown to target MIF to enhance cutaneous wound healing *via* the inactivation of macrophages, anti-inflammatory functions related to estrogen might contribute to the gender difference in the incidence of reflux esophagitis[98,99]. Conversely, other in *in vivo* studies revealed that estrogen promoted the pro-inflammatory response in macrophages *via* ER-α[100,101]. Interestingly, the cooperation of epidermal ER-α counter-regulator of ER-α and the activation of macrophage ER-αappeared to be required for the effective promotion of cutaneous wound healing[102].

Similar to macrophages and mast cells, neutrophils and lymphocytes are reported to express various sex steroid receptors, including ERs[103]. Although these inflammatory cells and their related cytokines are considered to be associated with the epithelial damage caused by harmful refluxate and the development of BE[104], the precise mechanism responsible for the development of BE or subsequent carcinogenesis has yet to be elucidated[104-108]. Some experimental models demonstrated that estrogen modulated the activation of neutrophils and lymphocytes *via* ER[103], whereas others that estrogen inactivated these cells[109]. Further study is needed to elucidate the mechanisms by which sex steroid hormones affect the GERD spectrum by altering the activity of inflammatory cells.

***Epithelial barrier functions***

A series of epidemiologic studies demonstrating a male predominance in the incidence of ERD and the subsequent metaplasia-carcinoma sequence have suggested that women are somewhat resistant to esophageal damage. To our knowledge, gender has not been shown to affect esophageal barrier function. In our recent preliminary study, estrogen enhanced the esophageal structural resistance to refluxed acid, concomitant with the up-regulated expression in esophageal occludin, a tight junctions protein that plays a crucial role in the esophageal mechanical defense system, which might explain the male predominance of GERDs[110]. A thorough study of the role of estrogen in enhancing the esophageal resistance and a more detailed understanding of the junctional proteins are needed[111].

**Hormone replacement therapy**

In this review, we demonstrated that estrogen in females could be responsible for the striking male predominance in the spectrum of GERDs. This potentially protective function might enable us to apply estrogen as a therapeutic agent for GERD patients. A few cohort studies have described that hormone replacement therapy (HRT) use in postmenopausal women was associated with a reduced risk of EAC[112,113]. Specifically, HRT was reported to reduce the risk of EAC in women by approximately 50%. However, a population-based, retrospective cohort study of men heavily exposed to estrogen revealed that this treatment did not reduce the risk of EAC[114]. In fact, HRT was associated with an increased risk of GERD. A similar positive association between post-menopausal HRT use and acid reflux symptoms has been reported in population-based studies[115]. This association between increased GERD risk and taking HRT was erased by examining endoscopic diagnoses for ERD[112]. These results suggest that HRT is likely to be associated with symptoms of GERD but not with esophageal tissue damage induced by gastric reflux.

In patients with GERD, reflux may result in the direct activation of pain receptors[116]. Several types of nociceptors have been identified in the esophagus and reported to be involved in the perception of reflux[117]. One of these pain receptors, the transient receptor potential cation channel subfamily V member 1 (TRPV1), has received particular attention in human GERD patients and is considered a primary receptor in the perception of acid reflux because it is activated by protons and responsive to pH values below 6[118]. Several studies have found that patients with GERD express higher levels of TRPV1 in their esophageal mucosa than patients without GERD, and distal esophageal TRPV1 expression has been shown to be higher in patients with NERD than in patients with ERD[119,120]. Despite the lack of evidence concerning the relationship between esophageal TRPV1 expression and sex steroid hormones, estrogen was reported to increase TRPV1 expression and contribute to pain transmission in a recent human study of endometriosis[121]. Thus, estrogen might contribute to enhance esophageal nociception female GERD patients. These findings might be related to several studies reporting that the incidence of NERD, *i.e.*, symptomatic GERD, is higher in women than in men, whereas the overall prevalence of GERD does not differ between men and women. Therefore, the modulation of the estrogen-related signal pathway may reduce the esophageal inflammation induced by gastric reflux and prevent the development of BE and EAC, but it may also enhance pain sensitivity to gastric reflux, which might be responsible for the higher incidence of symptomatic GERD in women than in men. Therefore, the simple administration of female sex hormones will not likely be an effective therapy for GERD patients.

**Conclusion**

Taken together, GERDs are significantly more common in men than in women. The dynamics in the prevalence of ERD, BE and EAC closely correlate with the reproductive status of women, which reflects the level of the sex hormone estrogen. This potential effect of estrogen could delay the development of BE and subsequent EAC *via* its anti-inflammatory function and acquisition of epithelial resistance in the esophagus against causative refluxate, which is likely responsible for the sex difference in the GERD spectrum. The identification of the crucial role of the estrogen-related endocrine milieu in GERD could contribute to establishing risk stratification for EAC and an endoscopy-based surveillance program for BE patients, the utility of which has yet to be validated[122]. Moreover, the elucidation of this mechanism could lead to new therapeutic strategies that might supersede conventional acid-suppressive medications, which have failed to completely prevent the esophageal carcinogenesis caused by GERD.

**References**

1 **Thrift AP**, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. *Ann Oncol* 2012; **23**: 3155-3162 [PMID: 22847812 DOI: 10.1093/annonc/mds181]

2 **Bosetti C**, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, Negri E, La Vecchia C. Trends in oesophageal cancer incidence and mortality in Europe. *Int J Cancer* 2008; **122**: 1118-1129 [PMID: 17990321 DOI: 10.1002/ijc.23232]

3 **Theisen J**, Peters JH, Stein HJ. Experimental evidence for mutagenic potential of duodenogastric juice on Barrett's esophagus. *World J Surg* 2003; **27**: 1018-1020 [PMID: 14560365 DOI: 10.1007/s00268-003-7055-z]

4 **Griffith GW**. The sex ratio in gastric cancer and hypothetical considerations relative to aetiology. *Br J Cancer* 1968; **22**: 163-172 [PMID: 5660128 DOI: 10.1038/bjc.1968.23]

5 **McMichael AJ**, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. *J Natl Cancer Inst* 1980; **65**: 1201-1207 [PMID: 7001123]

6 **Muir CS**, McKinney PA. Cancer of the oesophagus: a global overview. *Eur J Cancer Prev* 1992; **1**: 259-264 [PMID: 1467771 DOI: 10.1097/00008469-199204000-00007]

7 **Houdeau E**, Moriez R, Leveque M, Salvador-Cartier C, Waget A, Leng L, Bueno L, Bucala R, Fioramonti J. Sex steroid regulation of macrophage migration inhibitory factor in normal and inflamed colon in the female rat. *Gastroenterology* 2007; **132**: 982-993 [PMID: 17324399 DOI: 10.1053/j.gastro.2006.12.028]

8 **Aguwa CN**. Effects of exogenous administration of female sex hormones on gastric secretion and ulcer formation in the rat. *Eur J Pharmacol* 1984; **104**: 79-84 [PMID: 6542018 DOI: 10.1016/0014-2999(84)90371-6]

9 **Campbell-Thompson M**, Lauwers GY, Reyher KK, Cromwell J, Shiverick KT. 17Beta-estradiol modulates gastroduodenal preneoplastic alterations in rats exposed to the carcinogen N-methyl-N'-nitro-nitrosoguanidine. *Endocrinology* 1999; **140**: 4886-4894 [PMID: 10499548 DOI: 10.1210/endo.140.10.7030]

10 **Masaka T**, Iijima K, Endo H, Asanuma K, Ara N, Ishiyama F, Asano N, Koike T, Imatani A, Shimosegawa T. Gender differences in oesophageal mucosal injury in a reflux oesophagitis model of rats. *Gut* 2013; **62**: 6-14 [PMID: 22287598 DOI: 10.1136/gutjnl-2011-301389]

11 **Pope CE**. Acid-reflux disorders. *N Engl J Med* 1994; **331**: 656-660 [PMID: 8052276 DOI: 10.1056/NEJM199409083311007]

12 **Ronkainen J**, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Graffner H, Vieth M, Stolte M, Engstrand L, Talley NJ, Agréus L. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. *Scand J Gastroenterol* 2005; **40**: 275-285 [PMID: 15932168]

13 **El-Serag HB**, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. *Scand J Gastroenterol* 2002; **37**: 899-904 [PMID: 12229963 DOI: 10.1080/003655202760230847]

14 **Lin M**, Gerson LB, Lascar R, Davila M, Triadafilopoulos G. Features of gastroesophageal reflux disease in women. *Am J Gastroenterol* 2004; **99**: 1442-1447 [PMID: 15307857 DOI: 10.1111/j.1572-0241.2004.04147.x]

15 **Nilsson M**, Lundegårdh G, Carling L, Ye W, Lagergren J. Body mass and reflux oesophagitis: an oestrogen-dependent association? *Scand J Gastroenterol* 2002; **37**: 626-630 [PMID: 12126237 DOI: 10.1080/00365520212502]

16 **Jaspersen D**, Kulig M, Labenz J, Leodolter A, Lind T, Meyer-Sabellek W, Vieth M, Willich SN, Lindner D, Stolte M, Malfertheiner P. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. *Aliment Pharmacol Ther* 2003; **17**: 1515-1520 [PMID: 12823154 DOI: 10.1046/j.1365-2036.2003.01606.x]

17 **Ford AC**, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. *Am J Epidemiol* 2005; **162**: 454-460 [PMID: 16076833 DOI: 10.1093/aje/kwi218]

18 **Menon S**, Jayasena H, Nightingale P, Trudgill NJ. Influence of age and sex on endoscopic findings of gastrooesophageal reflux disease: an endoscopy database study. *Eur J Gastroenterol Hepatol* 2011; **23**: 389-395 [PMID: 21448069 DOI: 10.1097/MEG.0b013e328345d429]

19 **Furukawa N**, Iwakiri R, Koyama T, Okamoto K, Yoshida T, Kashiwagi Y, Ohyama T, Noda T, Sakata H, Fujimoto K. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. *J Gastroenterol* 1999; **34**: 441-444 [PMID: 10452674 DOI: 10.1007/s005350050293]

20 **Koike T**, Ohara S, Sekine H, Iijima K, Kato K, Shimosegawa T, Toyota T. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. *Am J Gastroenterol* 1999; **94**: 3468-3472 [PMID: 10606305 DOI: 10.1111/j.1572-0241.1999.01593.x]

21 **Ho KY**, Chan YH, Kang JY. Increasing trend of reflux esophagitis and decreasing trend of Helicobacter pylori infection in patients from a multiethnic Asian country. *Am J Gastroenterol* 2005; **100**: 1923-1928 [PMID: 16128934 DOI: 10.1111/j.1572-0241.2005.50138.x]

22 **Cook MB**, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. *Am J Epidemiol* 2005; **162**: 1050-1061 [PMID: 16221805 DOI: 10.1093/aje/kwi325]

23 **Moki F**, Kusano M, Mizuide M, Shimoyama Y, Kawamura O, Takagi H, Imai T, Mori M. Association between reflux oesophagitis and features of the metabolic syndrome in Japan. *Aliment Pharmacol Ther* 2007; **26**: 1069-1075 [PMID: 17877514 DOI: 10.1111/j.1365-2036.2007.03454.x]

24 **Richter JE**, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. *Arch Intern Med* 2000; **160**: 1803-1809 [PMID: 10871974 DOI: 10.1001/archinte.160.12.1803]

25 **Damiano A**, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. *Dig Dis Sci* 2003; **48**: 657-662 [PMID: 12741452 DOI: 10.1023/A: 1022812103923]

26 **Minatsuki C**, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, Sakaguchi Y, Nakayama C, Konno-Shimizu M, Matsuda R, Mochizuki S, Asada-Hirayama I, Tsuji Y, Kodashima S, Ono S, Niimi K, Mitsushima T, Koike K. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. *PLoS One* 2013; **8**: e69891 [PMID: 23922844 DOI: 10.1371/journal.pone.0069891]

27 **Spechler SJ**, Sharma P, Souza RF, Inadomi JM, Shaheen NJ; [American Gastroenterological Association](http://www.ncbi.nlm.nih.gov/pubmed/?term=American%20Gastroenterological%20Association%5BCorporate%20Author%5D). American Gastroenterological Association technical review on the management of Barrett's esophagus. *Gastroenterology* 2011; **140**: e18-52; quiz e13 [PMID: 21376939 DOI: 10.1053/j.gastro.2011.01.031]

28 [**ASGE Standards of Practice Committee**](http://www.ncbi.nlm.nih.gov/pubmed/?term=ASGE%20Standards%20of%20Practice%20Committee%5BCorporate%20Author%5D)**,** Evans JA, Early DS, Fukami N, Ben-Menachem T, Chandrasekhara V, Chathadi KV, Decker GA, Fanelli RD, Fisher DA, Foley KQ, Hwang JH, Jain R, Jue TL, Khan KM, Lightdale J, Malpas PM, Maple JT, Pasha SF, Saltzman JR, Sharaf RN, Shergill A, Dominitz JA, Cash BD; [Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy](http://www.ncbi.nlm.nih.gov/pubmed/?term=Standards%20of%20Practice%20Committee%20of%20the%20American%20Society%20for%20Gastrointestinal%20Endoscopy%5BCorporate%20Author%5D). The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. *Gastrointest Endosc* 2012; **76**: 1087-1094 [PMID: 23164510 DOI: 10.1016/j.gie.2012.08.004]

29 **Fitzgerald RC**, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O'Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, Moayyedi P, Lyratzopoulos G, de Caestecker J; [British Society of Gastroenterology](http://www.ncbi.nlm.nih.gov/pubmed/?term=British%20Society%20of%20Gastroenterology%5BCorporate%20Author%5D). British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut* 2014; **63**: 7-42 [PMID: 24165758 DOI: 10.1136/gutjnl-2013-305372]

30 **Rudolph RE**, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, Reid BJ. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. *Ann Intern Med* 2000; **132**: 612-620 [PMID: 10766679 DOI: 10.7326/0003-4819-132-8-200004180-00003]

31 **Conio M**, Cameron AJ, Romero Y, Branch CD, Schleck CD, Burgart LJ, Zinsmeister AR, Melton LJ, Locke GR. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. *Gut* 2001; **48**: 304-309 [PMID: 11171817 DOI: 10.1136/gut.48.3.304]

32 **Kubo A**, Cook MB, Shaheen NJ, Vaughan TL, Whiteman DC, Murray L, Corley DA. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. *Gut* 2013; **62**: 1684-1691 [PMID: 23355549 DOI: 10.1136/gutjnl-2012-303753]

33 **Bani-Hani K**, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. *J Natl Cancer Inst* 2000; **92**: 1316-1321 [PMID: 10944553 DOI: 10.1093/jnci/92.16.1316]

34 **van Blankenstein M**, Looman CW, Johnston BJ, Caygill CP. Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. *Am J Gastroenterol* 2005; **100**: 568-576 [PMID: 15743353 DOI: 10.1111/j.1572-0241.2005.40187.x]

35 **Anderson LA**, Murray LJ, Murphy SJ, Fitzpatrick DA, Johnston BT, Watson RG, McCarron P, Gavin AT. Mortality in Barrett's oesophagus: results from a population based study. *Gut* 2003; **52**: 1081-1084 [PMID: 12865262 DOI: 10.1136/gut.52.8.1081]

36 **Kulig M**, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. *Aliment Pharmacol Ther* 2003; **18**: 767-776 [PMID: 14535869 DOI: 10.1046/j.1365-2036.2003.01770.x]

37 **Pohl H**, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rösch T, Baumgart DC. Risk factors in the development of esophageal adenocarcinoma. *Am J Gastroenterol* 2013; **108**: 200-207 [PMID: 23247577 DOI: 10.1038/ajg.2012.387]

38 **Conio M**, Blanchi S, Lapertosa G, Ferraris R, Sablich R, Marchi S, D'Onofrio V, Lacchin T, Iaquinto G, Missale G, Ravelli P, Cestari R, Benedetti G, Macrì G, Fiocca R, Munizzi F, Filiberti R. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. *Am J Gastroenterol* 2003; **98**: 1931-1939 [PMID: 14499768 DOI: 10.1111/j.1572-0241.2003.07666.x]

39 **van Soest EM**, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. *Gut* 2005; **54**: 1062-1066 [PMID: 15857935 DOI: 10.1136/gut.2004.063685]

40 **de Jonge PJ**, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. *Gut* 2010; **59**: 1030-1036 [PMID: 20639249 DOI: 10.1136/gut.2009.176701]

41 **Ronkainen J**, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agréus L. Prevalence of Barrett's esophagus in the general population: an endoscopic study. *Gastroenterology* 2005; **129**: 1825-1831 [PMID: 16344051 DOI: 10.1053/j.gastro.2005.08.053]

42 **Hvid-Jensen F**, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med* 2011; **365**: 1375-1383 [PMID: 21995385 DOI: 10.1056/NEJMoa1103042]

43 **Hillman LC**, Chiragakis L, Clarke AC, Kaushik SP, Kaye GL. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma. *J Gastroenterol Hepatol* 2003; **18**: 526-533 [PMID: 12702044 DOI: 10.1046/j.1440-1746.2003.02965.x]

44 **Falk GW**, Thota PN, Richter JE, Connor JT, Wachsberger DM. Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer. *Clin Gastroenterol Hepatol* 2005; **3**: 1089-1094 [PMID: 16271339 DOI: 10.1016/S1542-3565(05)00606-3]

45 **Coleman HG**, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett's oesophagus: a population-based study. *Eur J Epidemiol* 2011; **26**: 739-745 [PMID: 21671079 DOI: 10.1007/s10654-011-9596-z]

46 **Masclee GM**, Coloma PM, de Wilde M, Kuipers EJ, Sturkenboom MC. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. *Aliment Pharmacol Ther* 2014; **39**: 1321-1330 [PMID: 24738722 DOI: 10.1111/apt.12759]

47 **Dong Y**, Qi B, Feng XY, Jiang CM. Meta-analysis of Barrett's esophagus in China. *World J Gastroenterol* 2013; **19**: 8770-8779 [PMID: 24379599 DOI: 10.3748/wjg.v19.i46.8770]

48 **Dubecz A**, Solymosi N, Stadlhuber RJ, Schweigert M, Stein HJ, Peters JH. Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?-a SEER Database Analysis. *J Gastrointest Surg* 2013; : [PMID: 24234242 DOI: 10.1007/s11605-013-2345-8]

49 **Lepage C**, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. *Am J Gastroenterol* 2008; **103**: 2694-2699 [PMID: 18853967 DOI: 10.1111/j.1572-0241.2008.02191.x]

50 **Ozawa S**. Comprehensive registry of esophageal cancer in Japan, 2002. *Esophagus* 2010; **7**: 7 [DOI: 10.1007/s10388-010-0228-6]

51 **Chang SS**, Lu CL, Chao JY, Chao Y, Yen SH, Wang SS, Chang FY, Lee SD. Unchanging trend of adenocarcinoma of the esophagus and gastric cardia in Taiwan: a 15-year experience in a single center. *Dig Dis Sci* 2002; **47**: 735-740 [PMID: 11991601 DOI: 10.1023/A: 1014771429546]

52 **Fernandes ML**, Seow A, Chan YH, Ho KY. Opposing trends in incidence of esophageal squamous cell carcinoma and adenocarcinoma in a multi-ethnic Asian country. *Am J Gastroenterol* 2006; **101**: 1430-1436 [PMID: 16863543 DOI: 10.1111/j.1572-0241.2006.00570.x]

53 **Voutilainen M**. Epidemiological trends in oesophageal cancer in the Nordic countries. *Scand J Gastroenterol* 2008; **43**: 323-327 [PMID: 18938769 DOI: 10.1080/17489530701699720]

54 **Mathieu LN**, Kanarek NF, Tsai HL, Rudin CM, Brock MV. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). *Dis Esophagus* 2014; **27**: 757-763 [PMID: 24118313 DOI: 10.1111/dote.12147]

55 **Derakhshan MH**, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. *Gut* 2009; **58**: 16-23 [PMID: 18838486 DOI: 10.1136/gut.2008.161331]

56 **Lagergren J**, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999; **340**: 825-831 [PMID: 10080844 DOI: 10.1056/NEJM199903183401101]

57 **Vaezi MF**, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. *Gastroenterology* 1996; **111**: 1192-1199 [PMID: 8898632 DOI: 10.1053/gast.1996.v111.pm8898632]

58 **Steevens J**, Botterweck AA, Dirx MJ, van den Brandt PA, Schouten LJ. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. *Eur J Gastroenterol Hepatol* 2010; **22**: 669-678 [PMID: 19474750 DOI: 10.1097/MEG.0b013e32832ca091]

59 **Enzinger PC**, Mayer RJ. Esophageal cancer. *N Engl J Med* 2003; **349**: 2241-2252 [PMID: 14657432 DOI: 10.1056/NEJMra035010]

60 **Pandeya N**, Olsen CM, Whiteman DC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. *Cancer Epidemiol* 2013; **37**: 579-584 [PMID: 23830137 DOI: 10.1016/j.canep.2013.05.011]

61 **Coleman HG**, Bhat S, Johnston BT, McManus D, Gavin AT, Murray LJ. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. *Gastroenterology* 2012; **142**: 233-240 [PMID: 22062359 DOI: 10.1053/j.gastro.2011.10.034]

62 **Freedman ND**, Derakhshan MH, Abnet CC, Schatzkin A, Hollenbeck AR, McColl KE. Male predominance of upper gastrointestinal adenocarcinoma cannot be explained by differences in tobacco smoking in men versus women. *Eur J Cancer* 2010; **46**: 2473-2478 [PMID: 20605442 DOI: 10.1016/j.ejca.2010.05.005]

63 **Thrift AP**, Pandeya N, Smith KJ, Mallitt KA, Green AC, Webb PM, Whiteman DC. Lifetime alcohol consumption and risk of Barrett's Esophagus. *Am J Gastroenterol* 2011; **106**: 1220-1230 [PMID: 21427711 DOI: 10.1038/ajg.2011.89]

64 **Corley DA**, Kubo A, Zhao W. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. *Gut* 2007; **56**: 756-762 [PMID: 17047097 DOI: 10.1136/gut.2006.109413]

65 **Corley DA**, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Quesenberry C, Rumore GJ, Buffler PA. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. *Gastroenterology* 2007; **133**: 34-41; quiz 311 [PMID: 17631128 DOI: 10.1053/j.gastro.2007.04.046]

66 **de Vries DR**, van Herwaarden MA, Smout AJ, Samsom M. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. *Am J Gastroenterol* 2008; **103**: 1349-1354 [PMID: 18510603 DOI: 10.1111/j.1572-0241.2008.01909.x]

67 **Pandolfino JE**, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. *Gastroenterology* 2006; **130**: 639-649 [PMID: 16530504 DOI: 10.1053/j.gastro.2005.12.016]

68 **Lee YY**, McColl KE. Disruption of the gastroesophageal junction by central obesity and waist belt: role of raised intra-abdominal pressure. *Dis Esophagus* 2015; **28**: 318-325 [PMID: 24575877 DOI: 10.1111/dote.12202]

69 **Wong A**, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. *Clin Gastroenterol Hepatol* 2005; **3**: 1-10 [PMID: 15645398 DOI: 10.1016/S1542-3565(04)00602-0]

70 **Merry AH**, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. *Gut* 2007; **56**: 1503-1511 [PMID: 17337464 DOI: 10.1136/gut.2006.116665]

71 **Massl R**, van Blankenstein M, Jeurnink S, Hermans JJ, de Haan MC, Stoker J, Koek M, Niessen WJ, Steyerberg EW, Looman CW, Kuipers EJ. Visceral adipose tissue: the link with esophageal adenocarcinoma. *Scand J Gastroenterol* 2014; **49**: 449-457 [PMID: 24467299 DOI: 10.3109/00365521.2013.873818]

72 **El-Serag HB**, Hashmi A, Garcia J, Richardson P, Alsarraj A, Fitzgerald S, Vela M, Shaib Y, Abraham NS, Velez M, Cole R, Rodriguez MB, Anand B, Graham DY, Kramer JR. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. *Gut* 2014; **63**: 220-229 [PMID: 23408348 DOI: 10.1136/gutjnl-2012-304189]

73 **Rubenstein JH**, Morgenstern H, Chey WD, Murray J, Scheiman JM, Schoenfeld P, Appelman HD, McMahon L, Metko V, Kellenberg J, Kalish T, Baker J, Inadomi JM. Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. *Gut* 2014; **63**: 230-235 [PMID: 23461896 DOI: 10.1136/gutjnl-2012-304103]

74 **Singh S**, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, Iyer PG. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 1399-1412.e7 [PMID: 23707461 DOI: 10.1016/j.cgh.2013.05.009]

75 **Shinkai H**, Iijima K, Koike T, Abe Y, Dairaku N, Inomata Y, Kayaba S, Ishiyama F, Oikawa T, Ohyauchi M, Ito H, Asonuma S, Hoshi T, Kato K, Ohara S, Shimosegawa T. Association between the body mass index and the risk of Barrett's esophagus in Japan. *Digestion* 2014; **90**: 1-9 [PMID: 25074386 DOI: 10.1159/000357776]

76 **Ford ES**, Li C, Zhao G, Tsai J. Trends in obesity and abdominal obesity among adults in the United States from 1999-2008. *Int J Obes (Lond)* 2011; **35**: 736-743 [PMID: 20820173 DOI: 10.1038/ijo.2010.186]

77 **Hsu IR**, Kim SP, Kabir M, Bergman RN. Metabolic syndrome, hyperinsulinemia, and cancer. *Am J Clin Nutr* 2007; **86**: s867-s871 [PMID: 18265480]

78 **Becker S**, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. *Arch Physiol Biochem* 2009; **115**: 86-96 [PMID: 19485704 DOI: 10.1080/13813450902878054]

79 **Considine RV**. Regulation of leptin production. *Rev Endocr Metab Disord* 2001; **2**: 357-363 [PMID: 11725722 DOI: 10.1023/A: 1011896331159]

80 **Ogunwobi O**, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. *Endocrinology* 2006; **147**: 4505-4516 [PMID: 16740977 DOI: 10.1210/en.2006-0224]

81 **Kendall BJ**, Macdonald GA, Hayward NK, Prins JB, Brown I, Walker N, Pandeya N, Green AC, Webb PM, Whiteman DC. Leptin and the risk of Barrett's oesophagus. *Gut* 2008; **57**: 448-454 [PMID: 18178609 DOI: 10.1136/gut.2007.131243]

82 **Rose DP**, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. *Maturitas* 2010; **66**: 33-38 [PMID: 20181446 DOI: 10.1016/j.maturitas.2010.01.019]

83 **Heine PA**, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. *Proc Natl Acad Sci USA* 2000; **97**: 12729-12734 [PMID: 11070086 DOI: 10.1073/pnas.97.23.12729]

84 **Cooke PS**, Heine PA, Taylor JA, Lubahn DB. The role of estrogen and estrogen receptor-alpha in male adipose tissue. *Mol Cell Endocrinol* 2001; **178**: 147-154 [PMID: 11403904 DOI: 10.1016/S0303-7207(01)00414-2]

85 **Clegg DJ**, Brown LM, Woods SC, Benoit SC. Gonadal hormones determine sensitivity to central leptin and insulin. *Diabetes* 2006; **55**: 978-987 [PMID: 16567519 DOI: 10.2337/diabetes.55.04.06.db05-1339]

86 **Quinton ND**, Smith RF, Clayton PE, Gill MS, Shalet S, Justice SK, Simon SA, Walters S, Postel-Vinay MC, Blakemore AI, Ross RJ. Leptin binding activity changes with age: the link between leptin and puberty. *J Clin Endocrinol Metab* 1999; **84**: 2336-2341 [PMID: 10404799 DOI: 10.1210/jcem.84.7.5834]

87 **Morita Y**, Iwamoto I, Mizuma N, Kuwahata T, Matsuo T, Yoshinaga M, Douchi T. Precedence of the shift of body-fat distribution over the change in body composition after menopause. *J Obstet Gynaecol Res* 2006; **32**: 513-516 [PMID: 16984520 DOI: 10.1111/j.1447-0756.2006.00437.x]

88 **Quinton ND**, Laird SM, Okon MA, Li TC, Smith RF, Ross RJ, Blakemore AI. Serum leptin levels during the menstrual cycle of healthy fertile women. *Br J Biomed Sci* 1999; **56**: 16-19 [PMID: 10492910]

89 **Choi JH**, Lee KT, Leung PC. Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth. *Carcinogenesis* 2011; **32**: 589-596 [PMID: 21173433 DOI: 10.1093/carcin/bgq276]

90 **Taylor AH**, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. *J Mol Endocrinol* 2000; **24**: 145-155 [PMID: 10657006]

91 **Gilliver SC**. Sex steroids as inflammatory regulators. *J Steroid Biochem Mol Biol* 2010; **120**: 105-115 [PMID: 20045727 DOI: 10.1016/j.jsbmb.2009.12.015]

92 **Kim MS**, Chae HJ, Shin TY, Kim HM, Kim HR. Estrogen regulates cytokine release in human mast cells. *Immunopharmacol Immunotoxicol* 2001; **23**: 495-504 [PMID: 11792009 DOI: 10.1081/IPH-100108596]

93 **Feldman MJ**, Morris GP, Dinda PK, Paterson WG. Mast cells mediate acid-induced augmentation of opossum esophageal blood flow via histamine and nitric oxide. *Gastroenterology* 1996; **110**: 121-128 [PMID: 8536848 DOI: 10.1053/gast.1996.v110.pm8536848]

94 **Frazier-Jessen MR**, Kovacs EJ. Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. *J Immunol* 1995; **154**: 1838-1845 [PMID: 7836768]

95 **Härkönen PL**, Väänänen HK. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. *Ann N Y Acad Sci* 2006; **1089**: 218-227 [PMID: 17261769 DOI: 10.1196/annals.1386.045]

96 **Bolego C**, Cignarella A, Staels B, Chinetti-Gbaguidi G. Macrophage function and polarization in cardiovascular disease: a role of estrogen signaling? *Arterioscler Thromb Vasc Biol* 2013; **33**: 1127-1134 [PMID: 23640494 DOI: 10.1161/ATVBAHA.113.301328]

97 **Wilson JM**, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E, Medina F, Brieva JA, Poulsom R, Markham AF, Bucala R, Hull MA. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. *Gastroenterology* 2005; **129**: 1485-1503 [PMID: 16285950 DOI: 10.1053/j.gastro.2005.07.061]

98 **Ashcroft GS**, Mills SJ, Lei K, Gibbons L, Jeong MJ, Taniguchi M, Burow M, Horan MA, Wahl SM, Nakayama T. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. *J Clin Invest* 2003; **111**: 1309-1318 [PMID: 12727922 DOI: 10.1172/JCI16288]

99 **Gilliver SC**, Emmerson E, Bernhagen J, Hardman MJ. MIF: a key player in cutaneous biology and wound healing. *Exp Dermatol* 2011; **20**: 1-6 [PMID: 21158933 DOI: 10.1111/j.1600-0625.2010.01194.x]

100 **Calippe B**, Douin-Echinard V, Delpy L, Laffargue M, Lélu K, Krust A, Pipy B, Bayard F, Arnal JF, Guéry JC, Gourdy P. 17Beta-estradiol promotes TLR4-triggered proinflammatory mediator production through direct estrogen receptor alpha signaling in macrophages in vivo. *J Immunol* 2010; **185**: 1169-1176 [PMID: 20554954 DOI: 10.4049/jimmunol.0902383]

101 **Campbell L**, Emmerson E, Williams H, Saville CR, Krust A, Chambon P, Mace KA, Hardman MJ. Estrogen receptor-alpha promotes alternative macrophage activation during cutaneous repair. *J Invest Dermatol* 2014; **134**: 2447-2457 [PMID: 24769859 DOI: 10.1038/jid.2014.175]

102 **Hardman MJ**, Emmerson E, Campbell L, Ashcroft GS. Selective estrogen receptor modulators accelerate cutaneous wound healing in ovariectomized female mice. *Endocrinology* 2008; **149**: 551-557 [PMID: 17974625 DOI: 10.1210/en.2007-1042]

103 **González DA**, Díaz BB, Rodríguez Pérez Mdel C, Hernández AG, Chico BN, de León AC. Sex hormones and autoimmunity. *Immunol Lett* 2010; **133**: 6-13 [PMID: 20637236 DOI: 10.1016/j.imlet.2010.07.001]

104 **Fitzgerald RC**, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. *Gut* 2002; **50**: 451-459 [PMID: 11889061 DOI: 10.1136/gut.50.4.451]

105 **Souza RF**, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. *Gastroenterology* 2009; **137**: 1776-1784 [PMID: 19660463 DOI: 10.1053/j.gastro.2009.07.055]

106 Yoshida N, Imamoto E, Uchiyama K, Kuroda M, Naito Y, Mukaida N, Kawabe A, Shimada Y, Yoshikawa T, Okanoue T. Molecular mechanisms involved in interleukin-8 production by normal human oesophageal epithelial cells. Alimentary pharmacology & therapeutics 2006; 24: 219 [DOI: 10.1111/j.1365-2036.2006.00049.x]

107 **Yamaguchi T**, Yoshida N, Tomatsuri N, Takayama R, Katada K, Takagi T, Ichikawa H, Naito Y, Okanoue T, Yoshikawa T. Cytokine-induced neutrophil accumulation in the pathogenesis of acute reflux esophagitis in rats. *Int J Mol Med* 2005; **16**: 71-77 [PMID: 15942680 DOI: 10.3892/ijmm.16.1.71]

108 **Souza RF**. The role of acid and bile reflux in oesophagitis and Barrett's metaplasia. *Biochem Soc Trans* 2010; **38**: 348-352 [PMID: 20298181 DOI: 10.1042/BST0380348]

109 **Aomatsu M**, Kato T, Kasahara E, Kitagawa S. Gender difference in tumor necrosis factor-α production in human neutrophils stimulated by lipopolysaccharide and interferon-γ. *Biochem Biophys Res Commun* 2013; **441**: 220-225 [PMID: 24140406 DOI: 10.1016/j.bbrc.2013.10.042]

110 **Günther C**, Neumann H, Vieth M. Esophageal epithelial resistance. *Dig Dis* 2014; **32**: 6-10 [PMID: 24603373 DOI: 10.1159/000357001]

111 **Oshima T**, Koseki J, Chen X, Matsumoto T, Miwa H. Acid modulates the squamous epithelial barrier function by modulating the localization of claudins in the superficial layers. *Lab Invest* 2012; **92**: 22-31 [PMID: 21912379 DOI: 10.1038/labinvest.2011.139]

112 **Menon S**, Nightingale P, Trudgill N. Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer? *United European Gastroenterol J* 2014; **2**: 374-382 [PMID: 25360315 DOI: 10.1177/2050640614543736]

113 **Green J**, Czanner G, Reeves G, Watson J, Wise L, Roddam A, Beral V. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. *Int J Cancer* 2012; **130**: 2387-2396 [PMID: 21671473 DOI: 10.1002/ijc.26236]

114 **Lagergren J**, Nyrén O. Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. *Cancer Epidemiol Biomarkers Prev* 1998; **7**: 913-915 [PMID: 9796637]

115 **Nilsson M**, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. *JAMA* 2003; **290**: 66-72 [PMID: 12837713 DOI: 10.1001/jama.290.1.66]

116 **Bredenoord AJ**. Mechanisms of reflux perception in gastroesophageal reflux disease: a review. *Am J Gastroenterol* 2012; **107**: 8-15 [PMID: 22218024 DOI: 10.1038/ajg.2011.286]

117 **Altomare A**, Guarino MP, Emerenziani S, Cicala M, Drewes AM, Krarup AL, Brock C, Lottrup C, Frøkjaer JB, Souza RF, Nardone G, Compare D. Gastrointestinal sensitivity and gastroesophageal reflux disease. *Ann N Y Acad Sci* 2013; **1300**: 80-95 [PMID: 24117636 DOI: 10.1111/nyas.12236]

118 **Holzer P**. Acid sensing by visceral afferent neurones. *Acta Physiol (Oxf)* 2011; **201**: 63-75 [PMID: 20456281 DOI: 10.1111/j.1748-1716.2010.02143.x]

119 **Guarino MP**, Cheng L, Ma J, Harnett K, Biancani P, Altomare A, Panzera F, Behar J, Cicala M. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. *Neurogastroenterol Motil* 2010; **22**: 746-51, e219 [PMID: 20456759 DOI: 10.1111/j.1365-2982.2010.01514.x]

120 **Yoshida N**, Kuroda M, Suzuki T, Kamada K, Uchiyama K, Handa O, Takagi T, Yoshikawa T, Kuramoto H. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. *Dig Dis Sci* 2013; **58**: 2237-2243 [PMID: 22899239 DOI: 10.1007/s10620-012-2337-7]

121 **Greaves E**, Grieve K, Horne AW, Saunders PT. Elevated peritoneal expression and estrogen regulation of nociceptive ion channels in endometriosis. *J Clin Endocrinol Metab* 2014; **99**: E1738-E1743 [PMID: 25029427 DOI: 10.1210/jc.2014-2282]

122 **Spechler SJ**, Souza RF. Barrett's esophagus. *N Engl J Med* 2014; **371**: 836-845 [PMID: 25162890 DOI: 10.1056/NEJMra1314704]

**P-Reviewer:** Adachi Y, Wong KKY **S-Editor:** Gong ZM

**L-Editor:** **E-Editor**

**Table 1 The male/female ratio in the prevalence of erosive esophagitis and non-erosive esophagitis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Authors** | **Country** | **Number** | **Study period** | **male/female ratio** |
| **Men** | **Women** |
| Erosive reflux esophagitis |
| United States | El-Serag *et al*[13], 2002 | United States | 4092 | 2617 | NA | 1.6 |
|  | Lin *et al*[14], 2004 | United States | 131 | 63 | NA | 1.6 |
| Europe | Nilsson *et al*[15], 2002 | Sweden | 108 | 71 | 1996-1997 | 1.6 |
|  | Jaspersen *et al*[16], 2003 | German/Austria/Switzerland | 1966 | 1279 | 2000-2001 | 1.6 |
|  | Ford *et al*[17], 2005 | United Kingdom | 1695 | 1301 | 2001-2003 | 1.4 |
|  | Menon *et al*[18], 2011 | United Kingdom | 13148 | 11092 | 1997-2009 | 1.2 |
| Asia | Furukawa *et al*[19], 1999 | Japan | 533 | 444 | 1996-1998 | 1.3 |
|  | Koike *et al*[20], 1999 | Japan | 98 | 78 | 1995-1998 | 1.3 |
|  | Ho *et al*[21], 2005 | Singapore | 649 | 479 | 1992-2001 | 1.4 |
| Non-erosive reflux esophagitis |
| United States | Richter *et al*[24], 2000 | United States | 375 | 523 | NA | 0.8 |
| Europe | Damiano *et al*[25], 2003 | United States | 73 | 150 | NA | 0.5 |
|  | Jaspersen *et al*[16], 2003 | German/Austria/Switzerland | 1337 | 1633 | 2000-2001 | 0.9 |
|  | Ronkainen *et al*[12], 2005 | Sweden | 340 | 431 | NA | 0.8 |

NA: non-applicable (data not available).

**Table 2 The male/female ratio in the prevalence of Barrett’s esophagus**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Authors** | **Country** | **Number** | **Study period** | **Male/female ratio** |
| **Men** | **Women** |
| Columnar lined epithelium with intestinal metaplasia |
| United States | Rudolph *et al*[30], 2000 | United States | 226 | 83 | 1993-1998 | 2.8 |
| Conio *et al*[31], 2001 | United States | 108 | 46 | 1969-1998 | 2.4 |
| Kubo *et al*[32], 2013 | United States/Ireland/Australia | 786 | 316 | 1997-2003 | 2.5 |
| Europe | Bani-Hani *et al*[33], 2000 | United Kingdom | 179 | 128 | 1984-1995 | 1.4 |
| van Blankenstein *et al*[34], 2005 | United Kingdom | 248 | 127 | 1982-1996 | 1.4 |
| Anderson *et al*[35], 2003 | Northern Ireland | 819 | 473 | 1993-1999 | 1.8 |
| Kulig *et al*[36], 2003 | Germany/Austria/Switzerland | 456 | 246 | 2000-2001 | 1.9 |
| Pohl *et al*[37], 2013 | Germany | NA | NA | 2005-2009 | 2.6 |
| Conio *et al*[38], 2003 | Italy | 135 | 31 | 1987-1997 | 4.4 |
| van Soest *et al*[39], 2005 | Netherlands | 158 | 102 | 1996-2003 | 1.6 |
| de Jonge *et al*[40], 2010 | Netherlands | NA | NA | 1996-2006 | 1.7 |
| Ronkainen *et al*[41], 2005 | Sweden | 9 | 7 | 1998 | 1.3 |
| Hvid-Jensen *et al*[42], 2011 | Denmark | 7366 | 3662 | 1992-2009 | 2.1 |
| Asia/Oceania | Hillman *et al*[43], 2003 | Australia | NA | NA | 1981-2001 | 2.5 |
| Columnar lined epithelium irrespective of intestinal metaplasia |
| Europe | Coleman *et al***[45]**, 2011 | Northern Ireland | 5482 | 3897 | 1993-2005 | 1.4 |
| Masclee *et al*[46], 2014 | United Kingdom | 7811 | 4501 | 2000-2011 | 1.8 |
| Netherlands | 856 | 527 | 2000-2012 | 1.7 |
| Asia | Dong *et al*[47], 2013 | China | 2452 | 1377 | 2001-2011 | 1.8 |

NA: non-applicable (data not available).

**Table 3 The male/female ratio in the prevalence of esophageal adenocarcinoma**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Authors** | **Ethnicity/ Country** | **Per million** | **Study period** | **Male/female ratio** |
| **Men** | **Women** |
| United States | Dubecz *et al*[48], 2013 | White | 40 | 11 | 1980 | 3.7 |
| Non white | 23 | 10 | 2.3 |
| White | 65 | 15 | 1990 | 4.4 |
| Non white | 30 | 19 | 1.6 |
| White | 90 | 20 | 2000 | 4.5 |
| Non white | 27 | 18 | 1.5 |
| Europe | van Soest *et al*[39]*,* 2005 | Netherlands | 39 | 12 | 1996-2003 | 3.3 |
| Lepage *et al*[49], 2008 | England and Wales | NA | NA | 1971-2001 | 5 |
| Hvid-Jensen *et al*[42], 2011 | Denmark | 56 | 10 | 1992-2009 | 5.6 |
| Pohl *et al*[37], 2013 | Germany | 87 | 23 | 2005-2009 | 3.8 |
| Hillman *et al*[43], 2003 | Australia | 11 | 2 | 1981-2001 | 5.5 |
| Asia/Oceania | Ozawa *et al*[50], 2010 | Japan | 3661 | 574 | 2002 | 6.4 |
| Chang *et al*[51], 2002 | Taiwan | 93% | 7% | 1981-1995 | 13.3 |
| Fernandes *et al*[52], 2006 | Singapore | 96 | 30 | 1968-2002 | 3.2 |

NA: non-applicable (data not available).